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Abstract BH3 mimetics have been proposed as new
anticancer therapeutics. They target anti-apoptotic Bcl-2
proteins, up-regulation of which has been implicated in the
resistance of many cancer cells, particularly leukemia and
lymphoma cells, to apoptosis. Using probabilistic compu-
tational modeling of the mitochondrial pathway of apop-
tosis, verified by single-cell experimental observations, we
develop a model of Bcl-2 inhibition of apoptosis. Our
results clarify how Bcl-2 imparts its anti-apoptotic role by
increasing the time-to-death and cell-to-cell variability. We
also show that although the commitment to death is highly
impacted by differences in protein levels at the time of
stimulation, inherent stochastic fluctuations in apoptotic
signaling are sufficient to induce cell-to-cell variability and
to allow single cells to escape death. This study suggests
that intrinsic cell-to-cell stochastic variability in apoptotic
signaling is sufficient to cause fractional killing of cancer
cells after exposure to BH3 mimetics. This is an unantic-
ipated facet of cancer chemoresistance.
Keywords Systems biology  Bcl-2  Apoptosis 
Stochastic variability  Cancer
Introduction
Apoptosis (programmed cell death) is an evolutionarily
conserved form of cell death which allows the removal of
damaged or superfluous cells in order to maintain tissue
homeostasis. It can be mediated by two pathways, the death
receptor pathway and the mitochondrial (intrinsic) path-
way. The latter is finely regulated up-stream of mito-
chondria by the concerted action of many molecules,
including a family of Bcl-2 proteins which consists of both
pro-apoptotic (BH3-only proteins and multidomain pro-
teins) and anti-apoptotic (Bcl-2-like proteins) members [1].
Interactions between these proteins control the process of
cytochrome c release from the mitochondrion, modulating
the sensitivity to cell death signals [1]. BH3-only proteins
belonging to this family have been suggested to induce cell
death by restraining the anti-apoptotic Bcl-2 proteins and/
or directly activating multidomain pro-apoptotic Bax/Bak
proteins [1, 2]. Interestingly, some of the oncogenic events,
such as genomic instability, oncogene activation or loss of
adhesion, can directly activate BH3-only proteins and
either induce or sensitize cells to apoptosis [3]. To modify
these death signals, cancer cells often increase the levels of
anti-apoptotic factors, such as Bcl-2, becoming dependent
on this anti-apoptotic protein [4, 5]. In such cells BH3
mimetics can induce apoptosis in a single agent treatment
scenario, by displacing the bound BH3-only proteins and
allowing activation of Bax/Bak [3].
Even though Bcl-2 inhibition of apoptosis has been
extensively studied in the past (reviewed in [6–8]), how
varying levels of a single form of anti-apoptotic Bcl-2-like
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protein translate into clear cell fate outcomes needs to be
elucidated at the molecular level. This becomes even more
important as recent mathematical and experimental studies
suggest that non-genetic cell-to-cell variability is central to
the signaling in the intrinsic pathway of apoptosis and seems
to explain an unusually slow cell death through this pathway
[9, 10]. A crucial feature of such variability is that a set of
genetically and epigenetically identical cells can respond to
an apoptotic stimulus in a very different manner [9–13].
Here, using a combination of probabilistic computational
modeling, flow cytometry and single-cell microscopy data,
we study the concentration-dependent variability in Bcl-2
inhibition of apoptosis. The experimentally-verified com-
putational model of apoptosis reproduces the behavior of a
heterogeneous population of cells treated with a BH3
mimetic and shows how varying levels of Bcl-2 regulate the
time-to-death (Td) and cell-to-cell variability in caspase
activation and cell death. Increased expression of Bcl-2
slows down apoptosis, increasing also the cell-to-cell vari-
ability in time to apoptotic death. Thus, a cell with partic-
ularly long time-to-death might escape apoptotic death and
initiate tumor formation. For cancer cells our results show
that treatment of a hypothetical population of identical
cancer cells still leads to fractional cell killing, which
results solely from the intrinsic stochastic variability in
chemical reactions. This challenges the concept that cell-to-
cell variability in execution of apoptosis arises only due to
genetic or epigenetic differences, or varying protein states
and concentrations, and clearly affects our expectations as
to the efficacy of apoptosis-targeted anticancer therapies.
Materials and methods
Cell culture and reagents
Jurkat leukemia T-cells were maintained in RPMI 1640
(Invitrogen) with L-glutamine, 1% penicillin/streptomycin
and 10% fetal bovine serum (FBS; Invitrogen) at 37C in
humidified 95% air, 5% CO2. Neuroblastoma SH-SY5Y
cells were maintained in advanced DMEM/F12 (1/1)
(Invitrogen), whereas HEK293 cells in DMEM (Invitro-
gen), supplemented as above. To induce apoptosis, cells
were treated with a small-molecule BH3 mimetic HA14-1
(Alexis Biochemicals). HA14-1 led to mitochondrial
membrane depolarization in all dying cells, as assessed by
flow cytometry combining 7-AAD and TMRM (below).
Analysis of apoptotic cell death
To assess cell viability, 0.3 9 106 Jurkat T cells or
0.1 9 106 SH-SY5Y cells were plated on 24-well plates,
and treated as indicated. At the end of the experiment, live
and dead cells were collected, washed with PBS, and
stained for 20 min at RT with Annexin V-PE (Invitrogen)
and 7-AAD (Invitrogen; 1 lg/sample) in the Annexin V
binding buffer (Invitrogen). The cells were analyzed
immediately on FACS Calibur (BD). Cells were gated
based on forward scatter (FSC) and side scatter (SSC) to
exclude cell debris, and next analyzed based on Annexin
V-PE fluorescence and 7-AAD fluorescence using Cell-
Quest (BD). Plots were generated using WinMDI 2.8.
Colony forming assay
SH-SY5Y cells were plated at 5 9 104 cells/well in
12-well plates. The next day the cells were treated with
DMSO or HA14-1 (12.5 lM) for 48 h. Cells were then
washed, and cultured in fresh medium. Cells were cultured
over 10–12 days in DMEM/F12 supplemented with 10%
FBS, penicillin/streptomycin, and glutamine. Medium was
replaced every 3 days. Cell colonies were stained with
Giemsa, fixed in 10% methanol, and cells photographed,
and then counted using ImageJ software.
Analysis of caspase 9 activity and multiparameter
(FLICA/TMRM/7-AAD) flow cytometry assay
Activation of caspase 9 was examined by a combination of
fluorescently labeled inhibitor of caspase (FLICA) FAM-
LEHD-FMK (Calbiochem) and 7-AAD (Invitrogen; 1 lg/
sample) as a probe of early plasma membrane permeability.
We have previously determined that the maximal fluores-
cence of FLICA reagent corresponds to the complete acti-
vation of caspase 9 [14]. Cells (0.15 9 106 per well) were
cultured for the time indicated with or without the indicated
doses of HA14-1, harvested, and incubated with FLICA for
45 min at 37C under 5% CO2 in darkness. Then, cells were
washed three times, stained with 7-AAD, and immediately
analyzed on a FACS Calibur (BD). For the three-color
analysis, FLICA-stained cells were also labeled with TMRM
(150 nM, Invitrogen) for 30 min at 37C under 5% CO2 in
darkness, followed by staining with 7-AAD and immediate
analysis. Cells were gated based on forward scatter (FSC)
and side scatter (SSC) to exclude cell debris, and based on
FSC versus 7-AAD to exclude cells with plasma membrane
permeability. Next cells were analyzed based on FLICA
fluorescence alone or in combination with analysis of
TMRM fluorescence. Plots were generated using WinMDA.
Time-lapse epifluorescent microscopy and digital
imaging
For analysis of cell-to-cell variability in time to death,
SH-SY5Y cells were treated in the presence of propidium
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iodide (PI; 0.5 lg/ml) to monitor appearance of dying cells
with loss of plasma membrane integrity. Image acquisition
was performed every 15 min. The presence of PI in tissue
culture media has been previously reported not to affect the
outcome of cytotoxicity assays [15]. To analyze cell-to-cell
variability in mitochondrial membrane depolarization,
SH-SY5Y cells and HEK293 cells were first equilibrated
with TMRM (200 nM; Invitrogen) in DMEM/F12 medium
and DMEM medium, respectively, for at least 2 h at 37C.
This approach to study of MOMP has the advantage of
avoiding the need for plasmid transfections and its asso-
ciated artifacts. After equilibration and baseline imaging,
cells were treated on stage with varying doses of HA14-1.
Image acquisition was performed for 4 h every 2 min.
Time-lapse imaging was performed on a Nikon Ti-E
inverted microscope (Nikon Corp., Kawasaki, Japan)
equipped with a ProScan H117 motorized XY stage and
NanoScan NZ250 piezo Z stage (both Prior Scientific
Instruments Ltd, Cambridge, UK), and an Andor iXon
DU-885 EM-CCD camera. The imaging setup was con-
trolled by Andor iQ v.1.9 software (Andor Technology Ltd,
Belfast, UK). A Semrock Cy3 4040B filter cube (excitation
531/40 nm, dichroic mirror 562 nm, emission 593/40 nm;
Semrock, Rochester, NY, USA) was used for epifluores-
cence. Cells were maintained at 37C with supplemental
CO2 using the incubator cabinet (Clear State Solutions Pty
Ltd, Melbourne, Australia).
Image processing
After background subtraction, the cellular TMRM fluo-
rescence intensity was calculated for each cell. At least ten
cells were analyzed for each treatment, with quantification
of 120 images per cell. Images were processed using
ImageJ. A difference of more then the SD below the initial
baseline, which did not recover to baseline values, was
defined as onset time of Dwm loss. In contrast to HA14-1,
the mitochondrial uncoupler FCCP led to simultaneous loss
of Dwm in all the cells (Fig. S1), confirming that cell-to-cell
variability in time to Dwm loss is not the intrinsic feature
related to TMRM labeling or functioning of the mito-
chondrial electron chain.
Computational systems analysis
We used a Monte Carlo stochastic simulation model of
apoptotic signaling reactions that explicitly simulates dif-
fusion and reaction moves at the level of individual mol-
ecules [11, 12]. At the beginning of the simulation all
signaling molecules are distributed randomly and uni-
formly in the cell volume simulated by a three dimensional
cubic lattice. Cytochrome c molecules were confined
within a fixed mitochondrial region inside the cell volume.
Once the concentration of active Bax dimers reaches a pre-
assigned threshold value (*0.017 lm), cytochrome c is
released from the mitochondria into the cytosol in an all-or-
none manner. Recent experiments indicate that only when
Bax activation reaches a threshold, formation of lipidic
pores in mitochondrial membrane leads to release of
cytochrome c [16], which justifies our model assumptions
regarding Bax dimerization-induced cytochrome c release.
Other mechanisms such as mitochondrial membrane
depolarization due to cumulative effects of Bax activation
would result in a qualitatively similar signaling response,
however, with a slightly modified time-scale of apoptosis
activation.
In our simulations, truncated Bid (tBid) initiates the
apoptotic signaling. At each attempt of Monte Carlo move,
a molecule is picked randomly, and either diffusion or a
reaction move is performed with pre-assigned probability
values. We assume mutual physical exclusion of signaling
molecules while carrying out the diffusion move. Thus, for
example, while performing a Monte Carlo move of binding
reactions two molecules that are on adjacent sites are
allowed to react. Explicit spatial simulation allows us to
model spatial localization such as: (a) translocation of
active Bax dimers onto mitochondrial membranes or
(b) clustering of multiple cytochrome c and APAF-1
molecules in an apoptosome assembly. In addition, explicit
spatial simulation allows us to assign differential diffusion
probability Pdiff for different types of free and complex
molecules. For example, multi-molecular apoptosome
complexes are assumed immobile in a crowded cellular
environment.
We defined separate functions for some general form of
reactions, such as (i) two molecules can bind in their free
binding pockets to form a complex with a probability Pon,
(ii) a molecule can dissociate from a multi-molecular
complex with a probability Poff, (iii) a signaling molecule,
while dissociating from a complex, can undergo confor-
mational change (or cleavage) to an active form with
probability Pcat. At the beginning of the simulation all the
molecules were placed in a random and uniform manner.
At each Monte Carlo attempt a randomly selected molecule
is allowed to undergo either diffusion or a reaction move.
In our simulations, we kept track of the number of mole-
cules of each signaling species over a period of time.
The proteins with similar biochemical activities were
represented by single species in our simulations. For
instance, caspase 7, which is functionally similar to caspase
3, as well as proteins functionally redundant to XIAP
(i.e., c-IAP1, c-IAP2 and NAIP), were not explicitly
included in our model. Similarly, Bcl-2 represented all
anti-apoptotic Bcl-2 family members, whereas Bax repre-
sented pore-forming proteins. Therefore, the protein con-
centrations varied in our simulations represent sums of
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functionally redundant protein concentrations. We studied
the effect of physiologically relevant protein variations in
apoptosis signaling by sampling Gaussian probability dis-
tributions. The physiologically relevant protein variations
refer to cell-to-cell variability in protein concentrations that
may exist at the time of application of an apoptotic stim-
ulus and originated from noisy gene expression [17–20].
The average of the distribution for a specific protein was
assumed to be the known average concentration for that
particular signaling species. We used a coefficient of var-
iation (CV, variance/mean) of 0.25 in the Gaussian distri-
butions for all signaling proteins [10, 20]. At the beginning
of our simulation we randomly sampled from respective
Gaussian distributions and assigned different concentra-
tions of proteins to individual simulation runs (single cells
in a population). We did not allow further protein additions
(de novo synthesis) or degradations during the course of
the simulation.
Estimates for model parameters, such as rates, initial
protein concentrations, and IC50 for HA14-1 binding to
Bcl-2 were obtained from the literature [9, 21–25]. An
earlier developed parameter-mapping scheme was used to
estimate the values of probabilistic constants, which are
directly used in our simulations, from experimentally
known values of physical variables [11–13]. In this
approach, the time-scale of simulation emerges naturally
from our Monte Carlo simulations rendering a direct
comparison with experimentally observed time-scales
possible.
Results
The complex nature of protein signaling networks, such as
apoptotic pathways, with multiple variables acting at the
same time, can be often best studied using a systems level
analysis. Therefore, using systems level information of the
apoptotic signaling reactions, we have developed a quan-
titative model of the mitochondrial pathway of apoptosis
(Fig. 1a). This approach is based on a probabilistic method
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Fig. 1 Probabilistic computational model of the intrinsic pathway of
apoptosis reproduces cell-to-cell variability in time-to-death.
a Schematic of the mitochondrial pathway network modeled in this
study. MOMP mitochondrial outer membrane permeabilisation, tBid
truncated Bid. b Cell-to-cell variability and time to activation of
caspase 9 depend on Bcl-2 concentration. Insets indicate the number
of Bcl-2 molecules, corresponding to *0.075 lM (45 molecules),
*0.75 lM (450 molecules), *3 lM (1800 molecules), and
*7.5 lM (4500 molecules). Time is measured in Monte-Carlo
(MC) simulation steps. 1 MC step = 10-4 s, hence time-scale shown
5 9 108 MC steps *15 h. c Upper panel time-lapse images of
SH-SY5Y cells treated with 10 lM HA14-1. Bright field image was
taken at time 0. Inset numbers, time (min) after treatment. Dead cells
become permeable to propidium iodide (PI). Lower panel the non-
cumulative frequency distribution in time-to-death for SH-SY5Y cells
treated with HA14-1 at concentrations indicated, as determined by
live-cell microscopy (n [ 70 for each condition)
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in which the reactivity of all the signaling molecules fol-
lows a stochastic, rather than deterministic behavior, and
probes the induction of cell death at a single cell level [11].
We simulated the induction of the mitochondrial path-
way of apoptosis by allowing the direct tBid–Bax reaction
to generate pro-apoptotic Bax dimers [2]. The input signal
used in the model was varying concentration of Bcl-2
available to inhibit tBid and Bax molecules, which exper-
imentally was recapitulated using a small molecule BH3
mimetic HA14-1 [21], previously shown to bind and titrate
down Bcl-2, relieving its inhibitory action on Bax (indirect
activation model) [26]. In our computational model cyto-
chrome c was released in an all-or-none manner once a
threshold number of Bax dimers (denoted as Bax2) are
formed. This is in line with recent experimental studies
suggesting that the release of cytochrome c occurs rapidly
(*5 min) once it is initiated [27, 28]. Our model assumes
also that cytochrome c, once released into the cytosol,
binds with Apaf-1 and dATP to form the apoptosome, with
subsequent activation of caspase 9 and caspase 3. The
release of Smac has been modeled to inhibit anti-apoptotic
XIAP proteins. XIAP can inhibit procaspase-9 as well as
activated molecules of caspase-9 and caspase-3 (Fig. 1a).
Active caspase 3 decreases the concentration of anti-
apoptotic XIAP, creating an effective positive feedback
loop in the pathway (Fig. 1a). The proteins with similar
biochemical activities were represented by single species in
our simulations. For example, Bax represents all pro-
apoptotic multi-domain Bcl-2 proteins (i.e., both Bax and
Bak), whereas Bcl-2 represents all anti-apoptotic Bcl-2
proteins (e.g., Bcl-2, Bcl-Xl, Mcl-1, etc.).
Using the simplified model of the mitochondrial path-
way of apoptosis we seek to understand how varying levels
of the anti-apoptotic Bcl-2 protein affect the cells com-
mitment to apoptosis and cell-to-cell variability in time-to-
death (Td). In order to make the computational modeling
amenable, the initial approach was to keep the coefficient
of variation (CV) of all protein concentrations equal to 0.
In a clonal cell population, which was used for experi-
mental validation of the model, the concentrations of pro-
teins regulating apoptosis are expected to vary, with CV
ranging from 0.21 to 0.28 [10]. Despite this approximation,
the time scale of apoptosis that emerges naturally from our
stochastic simulations show slow (approx. hours) activa-
tion that becomes prolonged with increasing Bcl-2 con-
centrations (Fig. 1b, Fig. S2), as also observed in our
experimental studies (Fig. 1c). With single-cell time lapse
microscopy we show also that cell-to-cell variability in Td
depends on the dose of HA14-1, and is particularly heter-
ogeneous at low doses of HA14-1 (Fig. 1c). This is reca-
pitulated well by our simplified model of apoptosis
showing an all-or-none activation of caspase 9 (and cas-
pase 3) with increasing cell-to-cell variability as the
concentration of Bcl-2 is increased (Fig. 1b, Fig. S2).
Importantly, cell-to-cell variability in Td cannot be com-
pletely abolished, and is not sensitive to reduction of
Bcl-2 levels below a certain threshold (here *0.75 lM)
(Fig. 1b). Intermediate Bcl-2 level (here *3 lM) allows
induction of apoptosis but with a long time lag before
caspases are activated and with very large cell-to-cell
variation. This explains how a rare cell might escape
apoptotic death and, if it has tumor-promoting features,
initiate or accelerate tumor growth. For very high Bcl-2
levels (here *7.5 lm), as possibly found only in some
cancer cells, apoptotic activation does not take place within
the time-scale of our simulations (*15 h). This seems to
explain unusual apoptosis resistance of cancer cells that
have high over-expression of Bcl-2.
We also calculated the probability of caspase activation
in order to characterize cell-to-cell stochastic fluctuations
with the decreasing concentration of Bcl-2 protein. The
combined effects of (a) all-or-none activation of caspase 9
and 3 at the single cell level, and (b) cell-to-cell fluctua-
tions lead to bi-modal probability distributions for acti-
vated caspase 9 (Fig. 2a) and caspase 3 (Fig. S3). Such
bi-modal probability distributions can be used to estimate
the ratio variance/average, which is a quantitative esti-
mate of cell-to-cell variability in apoptosis activation. If
we approximate the probability distributions as perfect
bi-modal curves, the ratio variance/average for caspase 3
activity is found to be C3[1-f(Bcl-2,t)], where f(Bcl-2,t)
denotes the fraction of cells in which caspase 3 has
undergone complete activation at a given time t. Clearly,
f(Bcl-2,t) decreases with increasing Bcl-2 concentration
thus indicating an increase in cell-to-cell variability due to
decreased Bcl-2 inhibition. We also determine the distri-
bution of caspase 9 activity in HA14-1-treated immortal-
ized Jurkat T-cell leukemia cells, using a multiparameter
flow cytometry assay based on FAM-LEHD-FMK (caspase
9 FLICA) reagent which binds to the activated caspase 9,
TMRM which labels energized mitochondria, and plasma
membrane integrity marker 7-AAD (Fig. 2b). Caspase 9
activity increases slightly in HA14-1-treated Jurkat T cells
that have lost the mitochondrial transmembrane potential
(Dwm) (Fig. 2b), as measured when cells are gated for
negative labeling by 7-AAD and for lack of changes in
forward versus side scatter. Another population of cells
exhibited loss of Dwm and over tenfold increase in FLICA
fluorescence (Fig. 2b). Importantly, the intermediate events
in terms of caspase activity are infrequent (\2%) (Fig. 2b),
in line with the concept of bistability. We also analyze
caspase 9 activation in Jurkat T cells treated with
increasing doses of HA14-1. With the increase in the dose
of HA14-1, the population of cells with activated caspase 9
becomes more abundant, with early caspase 9 activation
represented by a slight increase in FLICA fluorescence, and
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complete caspase 9 activation represented by over tenfold
increase in FLICA fluorescence, and with very sparse
(\5%) intermediate events (Fig. 2c). We also observed
such a bimodal distribution of caspase activity, with
infrequent intermediate events between the initial and full
caspase 9 activation, in SH-SY5Y cells (Fig. S4). Finally,
for a fixed Bcl-2 concentration, the simplified model of the
intrinsic pathway of apoptosis predicts well the kinetics of
caspase 9 activation observed in Jurkat T cells treated with
HA14-1 (Fig. 2d).
Next we asked whether variability upstream of mito-
chondria can explain cell-to-cell fluctuations in Td. In our
computational model, formation of a critical number of
Bax2 dimers leads to immediate release of mitochondrial
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cytochrome c. We studied the activation of Bax2 com-
plexes as we varied the concentration of Bcl-2 in our
simulations. Increasing the Bcl-2 concentration had a
strong impact on Bax activation, which slowed down in a
noticeable manner with significantly increased cell-to-cell
variability as measured by time-to-activation of Bax2
(Fig. 3a). This is also seen from analyzing cell-to-cell
variability in time to onset of the loss of TMRM fluores-
cence in SH-SY5Y cells. The onset of Bax translocation to
mitochondria and formation of Bax oligomers usually does
not differ significantly from the onset of the loss of mito-
chondrial transmembrane potential (Dwm), which can be
detected by decreased fluorescence of TMRM [29]. Pre-
vious studies have also indicated that the initial loss of
TMRM fluorescence coincides with MOMP and the release
of cytochrome c [30]. Here we observe that HA14-1-
induced loss of TMRM fluorescence (Fig. 3b) occurs with
large cell-to-cell variability which decreases with the
increase in the dose of HA14-1 (Fig. 3c, Fig. S5). Thus, our
computational model reproduces qualitatively the behavior
of cell population exposed to the BH3 mimietic. Cell-
to-cell variability in Bax activation, as observed in our
simulations, is non-genetic and arises due to inherent sto-
chasticity of signaling reactions. Such stochastic fluctua-
tions occur in the presence of a large number of Bax and
Bcl-2 molecules, and actually increases as the Bcl-2 con-
centration is increased [17–19]. Even though a large
number of Bax and Bcl-2 molecules are initially present in
cells, high Bcl-2 concentration can lead to activation of
only a few Bax molecules and thus can serve as a source of
signaling noise in apoptosis. Cell-to-cell variability in Bax2
activation is readily translated to cell-to-cell variability in
the release of cytochrome c. There is a second amplifica-
tion in cell-to-cell stochastic fluctuations post cytochrome c
release (compare 3a with 1b, and Fig. 3c with 1c), due to
low probability of apoptosome formation, but the impact of
Bcl-2 on the cell-to-cell variability remains preserved.
We also analyzed the kinetics of mitochondrial mem-
brane depolarization (Dwm) and activation of caspase 9
using TMRM/FLICA/7-AAD assay and flow cytometry.
Mitochondria are affected first by the treatment with
HA14-1, which initially does not induce caspase activation
(Fig. 3d). At a cell population level, loss of Dwm occurs
gradually rather then in an all-or-nothing fashion (Fig. 3d,
note the lack of clear separation between cell subpopula-
tions on y axis), and pro-longed treatment (C4 h) leads to
gradual accumulation of cells with maximum loss of Dwm.
Notably, caspase 9 activation is initiated with some delay
and in the population of cells with the lowest fluorescence
of TMRM (Fig. 3d). Moreover, at any time point, the
population of cells with activated caspase 9 was propor-
tionally low within live/early apoptotic cells, as they very
rapidly proceeded to cell death characterized by the plasma
membrane permeability to 7-AAD (Supplementary Table 1).
These data suggest that upon treatment with HA14-1
mitochondria act as the integrator of death signal, as sug-
gested previously [10, 13, 31], and confirms that cell-to-
cell variability in time-to-MOMP contributes significantly
to the observed cell-to-cell variability in Td.
We and others have repeatedly observed that exposure to
BH3 mimetics elicits a non-uniform reaction in a clonal cell
population [14], with cells responding at different time
points and some not responding at all (Fig. 1c, Fig. S6).
Genetic and epigenetic differences as well as subtle varia-
tions in protein concentrations and states contribute signif-
icantly to the experimentally observed bifurcation in cell
fate [10, 20]. The subtle cell-to-cell variability in protein
concentrations can arise due to noisy gene expressions even
within a set of genetically identical cells [17–20]. Here we
test how cell-to-cell variability in time-to-death (Td) is
affected by the inherent stochastic variability in apoptotic
signaling as compared with subtle physiologically-relevant
variations in protein concentrations. To this aim we include
in our model the explicit inhibition of Bcl-2 by HA14-1. We
then test cell-to-cell variability in Td as we vary the con-
centration of HA14-1 in the model and sample the Bcl-2
concentration from a Gaussian distribution with coefficient
of variation (CV) of 0.25 [10, 20] or 0 (hypothetical popu-
lation of identical cells), and mean concentration of 3.75 and
7.5 lM (Fig. 4, Fig. S7). We varied the concentrations of
other signaling proteins in the apoptotic pathway in the same
Fig. 2 Probabilistic computational model of the intrinsic pathway of
apoptosis predicts the kinetics and bi-modal distribution of caspase
activation. a Probability distribution of caspase 9 activation calcu-
lated from single cell activation data of caspase 9. Insets indicate the
number of Bcl-2 molecules, corresponding to *0.075 lM (45
molecules), *0.75 lM (450 molecules), and *3 lM (1800 mole-
cules). Time is measured in Monte-Carlo (MC) steps. 1 MC
step = 10-4 s. b Analysis of early caspase 9 activation in cells
treated with HA14-1 confirms rapid caspase 9 activation without
intermediate events. Jurkat T cells were treated with HA14-1 (15 lM)
for 6 h, labeled with FAM-LEHD-FMK (caspase 9 FLICA), TMRM
and 7-AAD, and analyzed by flow cytometry. Late apoptotic events
were excluded based on changes in 7-AAD versus forward scatter
plots. Region R2, cells with energized mitochondria and lack of
caspase 9 activation; region R3, cells with loss of Dwm and no or
initial caspase 9 activation; region R4, cells with loss of Dwm and full
caspase 9 activation. Note that there are nearly no intermediate events
between the regions R3 and R4. c Jurkat T cells were treated for 6 h
with HA14-1 at concentrations indicated, and analyzed as above.
Note a characteristic shoulder on FLICA fluorescence plots (marked
below the plots with ), probably indicative of early caspase 9
activation, as well as small number of cells having intermediate
caspase 9 activation. Cells with no caspase activation are marked with
, and cells with full caspase activation are marked with
. d Upper panel the kinetics of caspase activation, analyzed
using caspase 9 FLICA in 7-AAD negative Jurkat T cells treated with
DMSO or 10 lM HA14-1; lower panel probability distribution of
caspase 9 activation calculated from single cell activation data of
caspase 9, for 45 molecules of Bcl-2 (*0.075 lM)
b
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manner. The effect of subtle variations in protein levels
was to increase the cell-to-cell variability in activation of
caspase 9 and 3 (Fig. 4, Fig. S7). However, even when all
intra- and extracellular parameters are equal between the
cells, including lack of variations in protein concentration,
significant cell-to-cell variability in Td was observed in
response to the BH3 mimetic (Fig. 4, Fig. S7), leading to
fractional cell killing within the time scale of our analysis.
We thus show that commitment to cell death is largely
impacted due to differences in protein levels at the time of
stimulation (Figs. 1b, 4, Fig. S7), which is in agreement with
previous studies [10]. Commitment to cell death is also
subject to inherent stochastic variations in the molecular
signaling reactions, the impact of which depends on the
concentration of Bcl-2 (Fig. 1b, Fig. S2) or the dose of BH3
mimetic (Fig. 4, Fig. S7), and may cause decorrelation in Td
in cycloheximide-treated sister cells [10, 20, 32]. Notably,
such inherent stochastic variability in apoptotic signaling
reactions exists even in the presence of a large number of
molecules of each protein species at the time of treatment.
Inhibitory signaling reactions and complex network struc-
tures dynamically generate a few copy numbers of signaling
molecules (such as Bax2 dimers). Moreover, some signaling
reactions, such as apoptosome formation, can occur with
very low probability. Both factors could contribute to gen-
eration of noise in apoptotic signaling.
Discussion
Other studies have used mathematical models of apoptosis
based on ordinary differential equations [e.g., 10], whereas
this paper uses probabilistic computational modeling that
allows studies of cell-to-cell variability within a given cell
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line. We verify qualitatively our model of the intrinsic
pathway of apoptosis by using single-cell experimental
approach. To model the varying level of Bcl-2 protein
experimentally, we use BH3 mimetic HA14-1, which has
been previously shown to trigger the mitochondrial path-
way of apoptosis via the Bcl-2-Bax axis (26). Although we
can not exclude the possibility of off-target effects of
HA14-1, such as binding to other Bcl-2 family proteins, or
generation of ROS, which is associated not only with
degradation of small molecule BH3 mimetics but also with
mitochondrial stress, we use this system to provide general
qualitative verification of the computational model. Our
observations show that as the doses of BH3 mimetic
increase, the cell-to-cell variability in time to death, and
time to initial loss of mitochondrial potential, decrease. The
bi-stability in caspase activation is also experimentally
observed in cells treated with HA14-1. This is consistent
with the results of the computational model of the intrinsic
pathway of apoptosis, explaining how varying levels of
Bcl-2 regulate cell-to-cell variability in time-to-death (Td).
The model reveals that the time-scale for Bax activation as
well as its cell-to-cell variability is significantly increased
as the Bcl-2 level increases, especially beyond a threshold
Bcl-2 level (*0.75 lM). Bax activation, in turn, modu-
lates mitochondrial events in such a manner that Td, as
measured by caspase 9 and caspase 3 activation, and the
cell-to-cell variability in commitment to apoptosis preserve
the effect of large Bcl-2 variations. With the current
experimental approach we confirm qualitatively the find-
ings of the computational model. In the future more spe-
cific interfering with the function of Bcl-2, possibly with
the use of more stable and specific next generation BH3
mimetics, could help to achieve better quantitative agree-
ment with the model. Nevertheless, based on the present
findings we postulate that as cells with high Bcl-2 levels
submit to cell death with large cell-to-cell stochastic vari-
ability, a cell with a particularly long Td can escape
apoptosis. Such a long time to death may lead to single
cells escaping apoptosis, allow time to acquire other tumor
initiating features and finally clonal initiation of tumor
growth.
Using the experimentally-verified probabilistic model of
the intrinsic pathway of apoptosis we finally study the
phenomenon of fractional cancer cell killing which has
been widely observed both in vitro and in vivo. Treatments
that fail to accomplish complete eradication of cancer cells
lead to relapse and often an accelerated tumor growth that
exceeds that of the original tumor, particularly if surviving
cells have tumorigenic capacity [33, 34]. This is likely to
occur especially in cancers that have very common tumor-
initiating cells [35]. The heterogeneity in response of
cancer cells is often attributed to subtle differences intrinsic
to cancer cells or their microenvironment, variation in the
access of tumor cells to a drug, or drug insensitivity during
certain phases of cell cycle [10, 36]. Although these factors
can clearly influence the sensitivity of cancer cells to
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chemotherapy, as we also show for varying concentrations
of Bcl-2, we ask here what would be the outcome of BH3
mimetic treatment in a hypothetical population of identical
cancer cells, the behavior of which is not influenced by
epigenetic or genetic variations, de novo protein synthesis,
induction of survival pathways, or subtle variations in
protein concentration. This is achieved by maintaining
constant all parameters, but the dose of HA14-1. We
hypothesize that the very nature of apoptotic signaling is
such that single cells will be able to escape death. We show
that treatment of such a population of cancer cells still
leads to fractional cell killing which is attributed entirely to
the stochastic nature of apoptotic signaling, despite the
presence of a large number of molecules for each protein
species in the intrinsic pathway of apoptosis [17–19]. Our
observation challenges the widely appreciated concept of
anti-cancer treatments targeted to induce apoptosis. High
levels of Bcl-2 in cancer cells increase even further the
inherent cell-to-cell variations in cell fate, increasing the
likelihood of fractional cell killing. These observations
imply that a very high concentration of BH3 mimetic, most
likely incompatible with the survival of non-cancerous
cells, would be required to achieve certainty of killing the
whole population of cancer cells. Considering the inherent
cell-to-cell variability in the apoptotic pathway, approaches
that widen the therapeutic window of pro-apoptotic agents
(e.g., specific cancer-targeted delivery with bacterially
derived minicells [37], combinatorial treatments with drugs
that delay mitotic exit [38], or even with standard che-
motherapeutic agents [14, 39]), and thus allow significantly
increasing the local drug concentration/efficacy, could
provide better outcomes. Otherwise, the strategy of adap-
tive therapy [40], targeting cancer cell cycle or inducing
cancer cell senescence may be more effective than treat-
ment protocols aiming at killing all tumor cells.
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